The current state of adverse event reporting in hemophilia.

@article{Vulpen2017TheCS,
  title={The current state of adverse event reporting in hemophilia.},
  author={Lize F D van Vulpen and Giorgia Saccullo and Alfonso Iorio and Michael Makris},
  journal={Expert review of hematology},
  year={2017},
  volume={10 2},
  pages={
          161-168
        }
}
INTRODUCTION Replacement of the missing clotting factor is the mainstay of hemophilia treatment. Whilst historically many hemophilia patients were infected with blood-borne viruses transmitted via plasma-derived products, nowadays the formation of alloantibodies against the missing clotting factor is the main adverse event of treatment. Areas covered: This paper provides an overview of the current national and international adverse event reporting systems, what these surveillance schemes taught… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 76 REFERENCES

Alternative therapies for the management of inhibitors.

  • Haemophilia : the official journal of the World Federation of Hemophilia
  • 2016